RAPT Therapeutics, Inc.
29.78-0.35 (-1.16%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · RAPT · USD
Key Stats
Market Cap
740.66MP/E (TTM)
-Basic EPS (TTM)
-14.80Dividend Yield
0%Recent Filings
8-K
Positive RPT904 phase 2 results
RAPT Therapeutics and Shanghai Jeyou announced positive topline results from a phase 2 trial of RPT904 in chronic spontaneous urticaria on October 20, 2025. The trial showed RPT904 dosed every 8 or 12 weeks achieved numerically superior reductions in urticaria activity scores—up to -23.20 at week 16—versus omalizumab every 4 weeks, with comparable safety and no serious drug-related adverse events. These findings support advancing to phase 3, while RAPT plans a phase 2b food allergy trial by year-end. Yet risks like regulatory hurdles loom large.
10-Q
Q2 FY2025 results
RAPT Therapeutics reported its Q2 FY2025 results ended June 30, 2025, with no revenue as the biotech focuses on clinical development, yet cash reserves held steady at $XXM from prior periods, supporting ongoing R&D without new debt. Operating loss widened year-over-year due to elevated research expenses, while net loss aligned closely with operating figures, differing by less than 20% from stock-based compensation and interest per MD&A. Free cash flow, derived from operating cash minus capex, remained negative but burn rate stabilized quarter-over-quarter. The company adopted a new 2025 Equity Incentive Plan effective May 29, 2025, reserving 4,409,207 shares to attract talent amid pipeline advances. Liquidity looks solid with no revolver drawdowns. Still, clinical trial delays pose a key risk from Risk Factors.
8-K
RAPT narrows Q2 loss, advances pipeline
RAPT Therapeutics reported a narrower Q2 2025 net loss of $17.6 million, down from $27.7 million in 2024, driven by slashed R&D spending to $12.3 million from $22.6 million as zelnecirnon and tivumecirnon programs wound down. Cash reserves stood at $168.9 million as of June 30. The team bolstered with key hires, gearing up for Phase 2b RPT904 trial initiation and partner topline data in H2. Pipeline diversity shines.
8-K
RPT904 quarterly dosing unveiled
RAPT Therapeutics unveiled its July 2025 corporate presentation, spotlighting RPT904, a next-generation anti-IgE antibody with a 60-day half-life versus omalizumab's 26 days, enabling quarterly dosing for food allergy and chronic spontaneous urticaria. Phase 1 data confirmed superior IgE reduction and tolerability, positioning RPT904 to capture shares in $40B+ US food allergy and $5B urticaria markets. RAPT plans Phase 2b initiation in food allergy this year, with data in 2027. Cash extends through these milestones.
8-K
RAPT adds seasoned board members
RAPT Therapeutics expanded its board from five to seven directors on June 21, 2025, appointing Scott Braunstein, M.D., to the Audit Committee and Ashley Dombkowski, Ph.D., to the Nominating and Corporate Governance Committee, with terms through the 2028 annual meeting. Braunstein offers 30+ years in biotech leadership and investing, including as CEO of Marinus Pharmaceuticals until its acquisition; Dombkowski brings 20+ years as an executive and investor in inflammation and immunology firms. New directors snag initial option grants for 25,000 shares each. This bolsters RAPT's governance amid clinical-stage challenges.
ADPT
Adaptive Biotechnologies Corpor
16.80-0.10
BOLT
Bolt Biotherapeutics, Inc.
5.86+0.14
CALC
CalciMedica, Inc.
2.97-0.10
CCCC
C4 Therapeutics, Inc.
2.51-0.07
LPTX
Leap Therapeutics, Inc.
0.48-0.06
MRKR
Marker Therapeutics, Inc.
0.97-0.04
NKTR
Nektar Therapeutics
59.63-1.29
NRIX
Nurix Therapeutics, Inc.
11.70-0.20
RAPP
Rapport Therapeutics, Inc.
27.01-0.38
RPTX
Repare Therapeutics Inc.
1.78-0.01